Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Indigenous Women's Experiences With Perinatal Nursing Care: Beyond Deficit Narratives to Work Toward Sovereign Wellbeing.

ANS. Advances in nursing science·2026
Same author

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

The lancet. HIV·2026
Same author

Nurses' Perspectives on Cancer Care for People Who Experience Incarceration in British Columbia, Canada: Challenges and Opportunities.

The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres·2026
Same author

Neural Crest-Derived Stem Cell Secretomes and Extracellular Vesicles Disrupt Glioblastoma through Dual-Pathway Inflammatory Rebalancing.

Stem cell reviews and reports·2026
Same author

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.

medRxiv : the preprint server for health sciences·2026
Same author

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Apr 18, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

16.4K

Structured observations reveal slow HIV-1 CTL escape.

Hannah E Roberts1, Jacob Hurst2, Nicola Robinson3

  • 1The Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, Oxford University, Oxford, United Kingdom.

Plos Genetics
|February 3, 2015
PubMed
Summary
This summary is machine-generated.

Cytotoxic T-lymphocyte (CTL) escape variants in HIV-1 infection arise slowly over years, not weeks. Protective HLA types and CD8+ T-cell responses influence the timing of viral escape during primary infection.

More Related Videos

Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses
11:19

Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses

Published on: May 4, 2015

11.9K
High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

6.3K

Related Experiment Videos

Last Updated: Apr 18, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

16.4K
Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses
11:19

Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses

Published on: May 4, 2015

11.9K
High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

6.3K

Area of Science:

  • Immunology
  • Virology
  • Genetics

Background:

  • Cytotoxic T-lymphocyte (CTL) escape variants are known to emerge during HIV-1 infection.
  • The precise timing of CTL escape variant emergence during primary HIV-1 infection remains unclear, with estimates varying widely.

Purpose of the Study:

  • To investigate the timing and prevalence of CTL escape variants during the first three years of untreated primary HIV-1 infection.
  • To determine factors influencing the rate of CTL escape, including host HLA type and T-cell responses.

Main Methods:

  • Analysis of longitudinal HIV-1 gag, pol, and nef sequences from 125 adults in the SPARTAC trial.
  • Assessment of patient HLA type and CD8+ T-cell responses using IFN-γ ELISpot assays.
  • Correlation of sequence data with clinical and immunological data to determine the timing of CTL escape.

Main Results:

  • Most sequence variations at early time points were transmitted, not arising from rapid escape.
  • CTL escape occurred gradually over the first three years of infection, with a median of one escape event per patient.
  • Protective HLA types and measurable CD8+ T-cell responses were associated with faster escape, but escape still took over two years on average.

Conclusions:

  • CTL escape in HIV-1 is a slow evolutionary process, typically emerging over years rather than weeks.
  • Host genetic factors (HLA type) and immune responses (CD8+ T-cells) modulate the rate of viral escape.
  • Understanding the kinetics of CTL escape is crucial for developing effective HIV-1 treatment and prevention strategies.